The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Defining Device Success for Percutaneous Coronary Intervention Trials: A Position Statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology

DOI: 10.4244/EIJ-D-19-00552

1. Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; Division of Cardiology, Department of Internal Medicine, Taipei Veterans General
2. Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
3. Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; Cardialysis B.V., Rotterdam, Netherlands.
4. Department of Cardiovascular Diseases, Deutsches Herzzentrum München, Technische Universität München, and DZHK (German Centre for Cardiovascualr Research), partner site Munich Heart Alliance, both Munich, Germany.
5. Division of Cardiology, C.A.S.T., P.O. "G. Rodolico", Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele," University of Catania, Catania, Italy
6. Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland.
7. Cardialysis B.V., Rotterdam, Netherlands.
8. Baim Institute for Clinical Research, Boston, Massachusetts
9. Duke Clinical Research Institute, Durham, NC.
10. New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA.
11. Barts Heart Centre, London and Queen Mary University of London, London, UK; Section fo Cardiology, Yale University School of medicine, New Haven, CT, USA.
12. The Zena and Michael A. Wiener Cardiovascular Institute, The Icahn School of Medicine at Mount Sinai, New York, NY.
13. Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; Cardialysis B.V., Rotterdam, Netherlands.
14. School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, UK.
15. Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, UK.
16. NHLI, Imperial College London, London, UK, United Kingdom

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.

To read the full content of this article, please log in to download the PDF.

Percutaneous coronary intervention with implantation of drug-eluting stents has become the most commonly performed revascularization procedure in patients with symptomatic coronary artery disease. Continuous iterations of coronary devices incorporating changes in platform materials, geometry, strut thickness, drug-release mechanisms and anti-proliferative drugs, have progressively reduced the rate of device-related adverse clinical events, and objective performance criteria have been proposed for clinical and angiographic outcomes of drug-eluting stents.The rate of device success has been recognized as an intra-procedural endpoint to evaluate the mechanical ability to complete a procedure with the specific device assigned by protocol in randomized comparative trials. The European Commission and the U.S. Food and Drug Administration both provide guidance documents including the mechanistic evaluation of coronary stents which recommend operational definitions of device success. While the majority of clinical trials investigating drug-eluting stents have adopted this endpoint definition, inconsistencies in application limit the reliability of comparisons across different trials reporting device success rates. In addition, it is not uncommon that device success rates are not reported by investigators.A consistent definition of device success is essential to allow scientific comparisons of this technical performance endpoint between devices across different trials. Therefore, we performed a systematic evaluation of definitions and reporting of device success in clinical trials. We propose an extended definition as well as considerations for approaching the determination of the device success rates in future percutaneous coronary intervention trials.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article

EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update